Amgen (AMGN) — Company Research
Last Updated: 15 July 2026
Amgen Inc. (NASDAQ: AMGN) is one of the world's largest biotechnology companies, discovering, manufacturing and selling biologic medicines across general medicine, oncology, inflammation and rare disease. The investment debate in mid-2026 is finely balanced: sixteen brands are growing at double-digit rates and full-year guidance was raised in April, yet biosimilar erosion is accelerating across the legacy denosumab franchise (Prolia/XGEVA) and the market is waiting on pivotal Phase 3 obesity data for MariTide — the readout that could reset the company's growth profile — expected from the beginning of 2027. This research lays out the reported facts from primary filings so you can weigh the trade-offs yourself.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | Amgen Inc. |
| Ticker / Exchange | AMGN / NASDAQ |
| Sector | Healthcare — Biotechnology |
| Headquarters | Thousand Oaks, California, USA |
| Founded | 1980 |
| CEO / Leadership | Robert A. Bradway (Chairman & Chief Executive Officer since 2012) |
| Employees | Approximately 31,500 in over 50 countries (about 13,000 outside the US), per FY2025 Form 10-K |
| Market cap | ~$192.7bn (~$356 per share, 14 July 2026) |
| Revenue (FY2025) | $36,751m total revenues ($35,148m product sales + $1,603m other revenues) |
| Net income (FY2025) | $7,711m GAAP; diluted GAAP EPS $14.23 (non-GAAP EPS $21.84) |
| Dividend | $2.52 per share quarterly for 2026 (+6% year-over-year; ~$10.08 annualised, ~2.8% yield) — 14+ consecutive years of dividend growth |
| Fiscal year end | 31 December |
2. Bull & Bear Case
Bull Case
- Broad-based growth engine: Sixteen brands delivered double-digit sales growth in Q1 2026 and seventeen products are annualising at more than $1bn; growth is spread across Repatha (+36% in FY2025), EVENITY (+34%), TEZSPIRE (+52%), BLINCYTO (+28%), UPLIZNA (+73%) and TAVNEOS (+62%), reducing single-product dependency.
- MariTide obesity optionality: Phase 2 data showed up to ~20% average weight loss at 52 weeks without plateau on monthly (or less frequent) dosing; the Phase 3 MARITIME programme (MARITIME-1, ~3,500 patients; MARITIME-2 in type-2 diabetes; MARITIME-Switch launched Q1 2026) reads out from the beginning of 2027 and could give Amgen a differentiated entry into the biggest market in pharma.
- Raised guidance with elite margins: After a Q1 2026 beat, management raised FY2026 guidance to $37.1–38.5bn revenue and $21.70–23.10 non-GAAP EPS; non-GAAP operating margin was 45% in Q1 2026 and 46.1% for FY2025, among the best in large-cap biopharma.
- Deleveraging plus growing income stream: Long-term debt has fallen from $63.2bn at YE2023 (post-Horizon) to $50.0bn at YE2025, while the dividend was raised 6% for 2026 ($2.52/quarter) — the balance sheet is steadily rebuilding capacity for the next pipeline investment cycle.
Bear Case
- Accelerating biosimilar erosion of the denosumab franchise: Prolia sales fell 10% year-over-year in Q4 2025 and XGEVA fell 20%, with management explicitly guiding to "accelerated sales erosion" in 2026 as multiple biosimilars launch globally — a ~$6.5bn annual franchise is now in decline.
- Legacy drag and pricing pressure: Enbrel, Otezla (a $400m impairment was taken in Q3 2025) and mature biosimilar-exposed brands offset growth elsewhere, while net selling prices fell 2–3% across the portfolio and US policy pressure (IRA price negotiation, potential tariffs) builds.
- Obesity race is crowded and unforgiving: MariTide arrives years behind Eli Lilly and Novo Nordisk, Phase 2 showed meaningful gastrointestinal tolerability challenges at initiation, and pivotal data are not due until 2027 — any stumble removes the main upside catalyst embedded in the shares.
- Near-term regulatory and sentiment overhangs: TAVNEOS faces a 29 July 2026 FDA deadline tied to its confirmatory-evidence requirements, and July 2026 saw analyst caution (Morgan Stanley target trimmed to $333; Bank of America reiterating a Sell with $312 target) with consensus modelling a ~8% EPS decline for Q2 2026.
3. Business Segments
Amgen operates as a single human-therapeutics business; the practical revenue split is by product. FY2025 total revenues were $36,751m — the largest contributors:
| Segment | % of revenue | What it is |
|---|---|---|
| Prolia (denosumab) | 12.0% ($4,414m) | Osteoporosis biologic; now facing global biosimilar competition with erosion accelerating in 2026 |
| Repatha (evolocumab) | 8.2% ($3,016m) | PCSK9 cholesterol-lowering injection; +36% in FY2025 on volume growth |
| EVENITY (romosozumab) | 5.7% ($2,100m) | Bone-building osteoporosis biologic; +34% in FY2025 |
| TEPEZZA (teprotumumab) | 5.2% ($1,903m) | Thyroid eye disease therapy acquired with Horizon Therapeutics (2023) |
| BLINCYTO (blinatumomab) | 4.2% ($1,559m) | Bispecific T-cell engager for acute lymphoblastic leukaemia; +28% in FY2025 |
| All other products & other revenues | ~64.7% (~$23,759m) | Includes Enbrel, Otezla, XGEVA, KYPROLIS, TEZSPIRE, Nplate, KRYSTEXXA, UPLIZNA, TAVNEOS, IMDELLTRA, biosimilars (PAVBLU, WEZLANA, AMGEVITA and others) and royalty/collaboration income |
4. Business Model & Moat
How it makes money. Amgen discovers, develops, manufactures and sells biologic medicines, largely reimbursed by governments and private insurers. Product sales were $35.1bn of FY2025's $36.8bn total revenues, with the remainder from collaborations and royalties. The portfolio spans four therapeutic areas — general medicine (Repatha, EVENITY, Prolia), rare disease (TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS — largely from the $27.8bn Horizon Therapeutics acquisition completed in 2023), inflammation (Enbrel, Otezla, TEZSPIRE, AMGEVITA) and oncology (BLINCYTO, IMDELLTRA, KYPROLIS, Vectibix, biosimilars).
The moat. Biologics are hard to copy: complex manufacturing at scale, decades of process know-how, and an installed base of prescriber and payer relationships create high barriers. Amgen is also one of the few originators to run a large biosimilars business of its own (PAVBLU, WEZLANA, BEKEMV), turning the biosimilar threat into a revenue line — PAVBLU alone generated $700m in its first full year (FY2025). Patents remain the core protection, which is why the pipeline (MariTide, rocatinlimab, bemarituzumab, olpasiran) matters so much.
Cash generation and capital allocation. FY2025 free cash flow was $8.1bn (operating cash flow $9,958m less capital expenditures $1,858m), funding a growing dividend (~$5.2bn/year), debt paydown (long-term debt down $6.5bn in 2025) and R&D of $7.3bn (+22% year-over-year). No shares were repurchased in 2025 as deleveraging took priority.
5. Financial Health
All figures from Amgen earnings press releases and SEC filings (10-K/8-K, XBRL). Dividend/share is the total declared for each calendar year's quarterly payments.
| Fiscal Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| FY2021 | $25,979m | +2.2% | $10.28 | $17.10 | $7.04 | $33,222m |
| FY2022 | $26,323m | +1.3% | $12.11 | $17.69 | $7.76 | $37,354m |
| FY2023 | $28,190m | +7.1% | $12.49 | $18.65 | $8.52 | $63,170m |
| FY2024 | $33,424m | +18.6% | $7.56 | $19.84 | $9.00 | $56,549m |
| FY2025 | $36,751m | +10.0% | $14.23 | $21.84 | $9.52 | $50,005m |
The FY2023 jump in long-term debt funded the $27.8bn Horizon Therapeutics acquisition (closed October 2023), which also drove FY2024's revenue surge and depressed FY2024 GAAP EPS ($7.56) through acquisition-related amortisation and charges. FY2025 GAAP EPS of $14.23 was flattered by $2,651m of net other income (largely gains on equity investments) and includes a $400m Otezla intangible impairment; adjusted (non-GAAP) EPS of $21.84 grew 10%. FY2025 operating cash flow was $9,958m, capital expenditures $1,858m and depreciation & amortisation $5,167m.
| Quarter / Half | Revenue | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q1 2026 | $8,618m | $5.15 | $3.34 |
| Q4 2025 | $9,866m | $5.29 | $2.45 |
| Q3 2025 | $9,558m* | $5.64 | $5.93 |
| Q2 2025 | $9,178m* | $6.02 | $2.65 |
| FY2025 total | $36,751m | $21.84 | $14.23 |
*Q2 2025 revenue is product sales of $8,770m plus other revenues of $408m as reported; Q3 2025 revenue derived arithmetically from full-year and other reported quarters (press releases round to "$9.6bn, +12%"). Q3 2025 GAAP EPS ($5.93) exceeded non-GAAP ($5.64) because of large net gains on equity investments recorded in GAAP other income. Q1 2026 (reported 30 April 2026): revenue +6%, non-GAAP EPS +5%, and FY2026 guidance raised to $37.1–38.5bn revenue, GAAP EPS $15.62–17.10 and non-GAAP EPS $21.70–23.10.
6. Valuation Metrics
Raw metrics, July 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$192.7bn (~$356.57/share on 14 Jul 2026; ~540m shares outstanding) |
| Trailing P/E (GAAP) | ~24.8x (TTM GAAP EPS $14.37 = Q2 2025 $2.65 + Q3 2025 $5.93 + Q4 2025 $2.45 + Q1 2026 $3.34); note GAAP EPS over this period is materially affected by swings in unrealised equity-investment gains/losses |
| P/E (forward) | ~15.9x on the midpoint of raised FY2026 non-GAAP EPS guidance of $21.70–23.10 (~$22.40); ~21.8x on the midpoint of GAAP EPS guidance of $15.62–17.10 |
| P/S (TTM) | ~5.2x (market cap ~$192.7bn / TTM revenue ~$37.2bn) |
| Enterprise value | ~$238bn (market cap ~$192.7bn + total debt $57.3bn ($5,437m current portion + $51,886m long-term) − cash and cash equivalents $12.0bn, per 31 Mar 2026 balance sheet) |
| EV/EBITDA (TTM) | ~16.7x on FY2025 GAAP EBITDA of ~$14.2bn (operating income $9,080m + D&A $5,167m); GAAP operating income carries heavy acquisition-related amortisation and the $400m Otezla impairment — on FY2025 non-GAAP operating income ($16.2bn) plus D&A the multiple is materially lower |
| P/FCF | ~23.8x (market cap ~$192.7bn / FY2025 free cash flow ~$8.1bn; FCF = operating cash flow $9,958m − capital expenditures $1,858m per FY2025 cash flow statement) |
| 52-week high | $391.29 (all-time closing high $385.25 on 27 Feb 2026) |
| 52-week low | $269.77 |
| Short interest (% of float) | 2.37% (12.74m shares per the February 2026 settlement report; down from 2.79% in January 2026) |
| Days to cover | 4.31 (February 2026 report) |
7. What Are They Building
An obesity franchise. MariTide (maridebart cafraglutide), a monthly-or-less-frequent GIPR/GLP-1 injectable, showed up to ~20% average weight loss at 52 weeks in Phase 2 without a plateau. The Phase 3 MARITIME programme spans obesity (MARITIME-1, ~3,500 participants), obesity with type-2 diabetes (MARITIME-2), a switch study from weekly GLP-1s (MARITIME-Switch, started Q1 2026) and cardiovascular-outcomes work, with primary readouts guided from the beginning of 2027. Commercial leadership has publicly positioned MariTide as potentially "the best monthly or less frequently dosed agent" in obesity.
The next wave of Phase 3 molecules. Beyond MariTide, late-stage assets include rocatinlimab (atopic dermatitis), bemarituzumab (gastric cancer), olpasiran (Lp(a) reduction for cardiovascular risk) and expanding indications for IMDELLTRA (small-cell lung cancer) and UPLIZNA (IgG4-related disease, generalised myasthenia gravis). R&D spend rose 22% in FY2025 to $7.3bn to fund this wave.
Scale manufacturing and biosimilars. Amgen is investing in US manufacturing capacity (including new plants in Ohio and North Carolina) and building out its biosimilars unit — PAVBLU (aflibercept biosimilar) delivered $700m in its first full year, WEZLANA (ustekinumab) $273m — providing a counter-cyclical revenue stream as its own legacy biologics face biosimilar competition.
8. Peer Comparison
| Peer | Market cap (July 2026) | Key 2025 metric |
|---|---|---|
| Eli Lilly (LLY) | ~$1,150bn | Obesity/diabetes leader (Zepbound, Mounjaro) — the incumbent MariTide must challenge |
| Johnson & Johnson (JNJ) | ~$621bn | Diversified pharma & medtech; largest US healthcare company by revenue |
| AbbVie (ABBV) | ~$445bn | Immunology peer managing its own patent cliff (Humira) via Skyrizi/Rinvoq growth |
| Gilead Sciences (GILD) | ~$158bn | Closest large-cap biotech comparable by size; HIV-led portfolio |
Peer market caps as reported by public market-data aggregators in early July 2026; figures move daily and should be re-checked at the time of reading.
9. Insider Activity
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Robert A. Bradway (Chairman & CEO) | 16 Mar 2026 | Tax withholding (F-code) | 21,294 | $366.21 | ~$7.8m | Shares withheld to cover tax on vesting equity — not an open-market sale |
| Robert A. Bradway (Chairman & CEO) | 05 May 2026 | Grant | 12,136 RSUs + 79,176 options | $329.59 (option strike) | — | Annual Equity Incentive Plan award, vesting 25%/year from May 2027 |
| Robert A. Bradway (Chairman & CEO) | 06 May 2026 | Tax withholding (F-code) | 1,702 | $329.59 | ~$0.6m | Shares withheld for tax — not an open-market sale |
2026 Form 4 filings show routine equity awards and tax-withholding dispositions; there have been no material insider open-market purchases or sales reported this year. Chairman & CEO Robert A. Bradway directly holds around 507,000 shares after these transactions.
10. Key Risks
- Biosimilar erosion: Prolia and XGEVA (denosumab, ~$6.5bn combined FY2025 sales) face multiple global biosimilar launches with management guiding to accelerated erosion through 2026; Enbrel and Otezla continue to decline, and RAVICTI faces generic competition.
- Pipeline/binary-event risk: The MARITIME Phase 3 obesity readouts (from early 2027) are the single biggest swing factor for the shares; Phase 2 gastrointestinal tolerability issues and formidable competition from Eli Lilly and Novo Nordisk make outcomes uncertain.
- Regulatory risk: TAVNEOS faces a 29 July 2026 FDA deadline linked to confirmatory-evidence requirements; more broadly, IRA Medicare price negotiation, potential US pharmaceutical tariffs and drug-pricing policy could compress US net prices (already down 2–3% portfolio-wide).
- Balance-sheet risk: Total debt was still $57.3bn at 31 March 2026 against $12.0bn of cash; while deleveraging is on track, higher-for-longer rates raise refinancing costs and constrain large-scale M&A.
- Concentration in the US market: Roughly three-quarters of product sales are US-derived, exposing Amgen to a single payer/policy environment.
- Litigation and tax risk: Amgen carries long-running IRS transfer-pricing disputes (multi-billion-dollar claimed deficiencies for 2010–2015) and routine patent litigation, either of which could produce material one-off charges.
11. Recent Developments
- 30 Apr 2026 — Q1 2026 beat and raised guidance. Total revenues rose 6% to $8.62bn; non-GAAP EPS of $5.15 beat consensus (~$4.77) and GAAP EPS rose 4% to $3.34 as GAAP operating margin expanded 17.4 points to 32.4%. FY2026 guidance was raised to $37.1–38.5bn revenue and $21.70–23.10 non-GAAP EPS; sixteen brands grew double-digit and free cash flow was $1.5bn.
- 03 Feb 2026 — FY2025 results: double-digit top and bottom-line growth. FY2025 total revenues rose 10% to $36.8bn (13% volume growth), non-GAAP EPS rose 10% to $21.84 and free cash flow was $8.1bn. Repatha (+36%), EVENITY (+34%) and TEZSPIRE (+52%) led growth while management flagged accelerated 2026 erosion for Prolia/XGEVA from biosimilars.
- 23 Jun 2025 — Full MariTide Phase 2 data at ADA. Amgen presented 52-week Phase 2 results showing up to ~20% average weight loss in obesity (2.6% placebo) and ~17% with type-2 diabetes, with weight loss not plateaued; the Phase 3 MARITIME programme is enrolling with primary readouts guided from the beginning of 2027, including the MARITIME-Switch study launched in Q1 2026.
- 14 Jul 2026 — Analyst caution ahead of Q2 results. The shares closed at $355.25 (−1.44% on the day); Morgan Stanley trimmed its target to $333 (Equal Weight) and Bank of America reiterated a Sell with a $312 target, with Q2 2026 consensus modelling EPS of ~$5.55 (−8% year-over-year) on revenue of ~$9.45bn. ChartsView does not use analyst opinions in its own assessment; these are noted purely as market-moving events.
12. Key Dates & What to Watch
- 29 Jul 2026 — FDA deadline concerning TAVNEOS confirmatory-evidence requirements — watch for a resolution or withdrawal decision
- 04 Aug 2026 — Q2 2026 results and earnings call (1:30pm PDT, per Amgen's investor-relations events calendar) — watch Prolia/XGEVA erosion pace versus growth-brand momentum
- Expected Sep 2026 — next quarterly dividend payment ($2.52 per share run-rate)
- Expected Oct 2026 — Q3 2026 results (early November in prior years; date to be confirmed by the company)
- Expected Jan 2027 — MARITIME-1 and MARITIME-2 Phase 3 primary readouts window opens ("beginning of 2027" per company guidance) — the pivotal catalyst for the obesity thesis
Track AMGN price action on our Live Charts, upcoming macro catalysts on the Economic Calendar, and join the discussion in the ChartsView Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Loading research report…
13. Thesis Verdict
The central thesis. Amgen is one of the world's largest biotechnology companies, selling biologic medicines across general medicine, rare disease, inflammation and oncology, with product sales of $35.1bn out of FY2025 total revenues of $36.8bn (+10%). Non-GAAP EPS rose 10% to $21.84 in FY2025, and after a Q1 2026 beat management raised full-year guidance to $37.1–38.5bn of revenue and $21.70–23.10 of non-GAAP EPS, with sixteen brands growing at double-digit rates. The pivotal growth driver is MariTide, Amgen's monthly obesity injectable, whose Phase 3 MARITIME readouts are guided from the beginning of 2027.
What would confirm or break it. Confirmation would come from Q2 2026 results (4 August 2026) showing the growth portfolio outpacing legacy erosion, continued deleveraging, and clean progression of the MARITIME programme. The thesis breaks if the "Biosimilar erosion" risk overwhelms growth — management already guides to accelerated Prolia/XGEVA declines in 2026 — or if MariTide stumbles on efficacy or tolerability against entrenched competition from Eli Lilly and Novo Nordisk, removing the main upside catalyst while ~$57bn of total debt still sits on the balance sheet.
Watchpoints
- ConfirmsQ2 2026 earnings (20 days) landing in line with or above management guidance.
- ConfirmsEvidence supporting the "Broad-based growth engine:" thesis continuing to build across subsequent filings.
- InvalidatesMaterialisation of the "Biosimilar erosion:" risk, or any disclosure that fundamentally alters the capital-return or growth profile stated by management.
Diagnostic grid
Generated by ChartsView research tooling. Thesis strength measures how well the evidence in this report supports the company's stated thesis — it is NOT a buy/sell rating or price target. ChartsView is not authorised by the FCA to provide regulated investment advice. Generated 15 Jul 2026.